Summit Therapeutics Shares Rise After Bernstein SocGen Upgrade
Summit Therapeutics (SMMT) shares rose 1.1% in pre-market trading after Bernstein SocGen upgraded the company to Market Perform from Underperform and raised its price target to $11.90 from $9.80. The broker cited Summit's current valuation as more reflective of ivonescimab's risk-adjusted value, though it remains cautious about the drug's broad market potential. Summit shares have been trading near their 52-week low of $12.07, down 57% from their high of $30.05.
How this was made
The 30-second read
Why it matters
The upgrade lifts sentiment and may attract short‑term buyers, but long‑term risk remains due to competitive pressures and pending FDA decision.
Market read
Analyst upgrade provides a fresh catalyst for a stock near its 52‑week low, offering a modest trading opportunity.
What to watch
Regulatory timeline extends to November 2026; any delay could negate the short‑term upside.
Background
Summit Therapeutics is a clinical‑stage biotech focused on ivonescimab, a PD‑1/VEGF bispecific antibody in Phase 3 trials.
Ticker impact
Bernstein SocGen upgraded Summit Therapeutics to Market Perform and raised the price target to $11.90, prompting a 1.1% pre‑market gain.
Potential modest upside toward the new $11.90 target over the next few days.
Analyst upgrade with a higher target provides a fresh catalyst; the stock is trading near its 52‑week low, making the move actionable.
Market effects
Positive sentiment may spill over to other biotech firms with late‑stage oncology pipelines.
Limited to US biotech sector; broader market conditions were supportive.
Minimal global impact beyond US investors.
Counterpoint
The upgrade may be premature given the drug's limited chance to displace established therapies like Keytruda.
Key entities
- AnalystBernstein SocGen
Upgraded Summit Therapeutics to Market Perform and raised price target.
- CompanySummit Therapeutics
Biotech developing ivonescimab.